Biogenerics 2005: A New Level of Complexity
Biogenerics (or biosimilars, or follow-on proteins) could now enter the EU market in a matter of months, and the US by 2009.
April 10, 2007 (Press Release) --
Biogenerics (or biosimilars, or follow-on proteins) could now enter the EU market in a matter of months, and the US by 2009. The prize awaiting biogeneric manufacturers such as Sandoz, Teva, and BioPartners is a global market worth $20 billion. Market fragmentation, product-specific constraints and new challenges in biotechnology, drug delivery and marketing will present major barriers to entry.
Scope of this report
In-depth analysis of product types and brands under threat, their suitability for biogenerics, and the forecast impact of biogenerics
Coverage of 25 biogenerics companies, their portfolios, partnerships and strategy, and analysis of improved, proprietary 'superbiogenerics'
Outline of regulatory progress, likely approval routes for biogenerics, and conflicting market pressures
Analysis of branded companies' franchises under threat, their strategies to deal with biogenerics, and their likely success
Research and analysis highlights
The EU regulatory pathway has progressed rapidly over the last two years, and It expects the first biogeneric to be approved by 2006. In the US immediate progress depends on the FDA's use of the controversial 505(b)(2) pathway for insulin and growth hormone.
Biogenerics will require an entirely new development and marketing strategy: marketing and patient support will be much more important, and this will favour companies with strong financial resources and commercial experience. Further in the future, the development of 'superbiogenerics' (second-generation biogenerics), will be a vital opportunity.
Different product types will differ greatly in their suitability as targets for biogenerics. Market size and patent expiry are not the only two considerations, as proven by the minimal interest in insulin. Epoetin, CSFs and human growth hormone are expected to account for the majority of the $2.2 billion in forecast biogeneric sales by 2010.
Key reasons to read this report
Identify key potential partners and competitors in the emerging biogenerics industry and examine their products and strategies
Discover the advantages and drawbacks of key biogeneric product types, and learn the forecast levels of biogeneric competition within each class
Analyze and benchmark branded companies' strategies to maintain market share and their likely success
Table of Contyents
CHAPTER 1 EXECUTIVE SUMMARY
4
Scope
4
It's opinion on the future of the biogenerics market
4
Related Reports :
Biotechnology: Global Industry Guide
Biogenerics 2005: A New Level of Complexity
Strategies for Biogeneric Success
Global Pharmaceuticals & Biotechnology
For more information kindly visit
http://www.bharatbook.com/detail.asp?id=10654
Scope of this report
In-depth analysis of product types and brands under threat, their suitability for biogenerics, and the forecast impact of biogenerics
Coverage of 25 biogenerics companies, their portfolios, partnerships and strategy, and analysis of improved, proprietary 'superbiogenerics'
Outline of regulatory progress, likely approval routes for biogenerics, and conflicting market pressures
Analysis of branded companies' franchises under threat, their strategies to deal with biogenerics, and their likely success
Research and analysis highlights
The EU regulatory pathway has progressed rapidly over the last two years, and It expects the first biogeneric to be approved by 2006. In the US immediate progress depends on the FDA's use of the controversial 505(b)(2) pathway for insulin and growth hormone.
Biogenerics will require an entirely new development and marketing strategy: marketing and patient support will be much more important, and this will favour companies with strong financial resources and commercial experience. Further in the future, the development of 'superbiogenerics' (second-generation biogenerics), will be a vital opportunity.
Different product types will differ greatly in their suitability as targets for biogenerics. Market size and patent expiry are not the only two considerations, as proven by the minimal interest in insulin. Epoetin, CSFs and human growth hormone are expected to account for the majority of the $2.2 billion in forecast biogeneric sales by 2010.
Key reasons to read this report
Identify key potential partners and competitors in the emerging biogenerics industry and examine their products and strategies
Discover the advantages and drawbacks of key biogeneric product types, and learn the forecast levels of biogeneric competition within each class
Analyze and benchmark branded companies' strategies to maintain market share and their likely success
Table of Contyents
CHAPTER 1 EXECUTIVE SUMMARY
4
Scope
4
It's opinion on the future of the biogenerics market
4
Related Reports :
Biotechnology: Global Industry Guide
Biogenerics 2005: A New Level of Complexity
Strategies for Biogeneric Success
Global Pharmaceuticals & Biotechnology
For more information kindly visit
http://www.bharatbook.com/detail.asp?id=10654
Email
Print
SPAM
